The goal of this program is to improve management of bladder cancer using novel approaches. After hearing and assimilating this program, the clinician will be better able to:
1. Differentiate between classic MVAC and dose-dependent MVAC.
2. Explain the significance of cisplatin ineligibility in the KEYNOTE-052 trial.
3. Cite the benefits of atezolizumab in management of metastatic urothelial cancer based on evidence from IMvigor210.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Urology
- Start Date: 2022-05-04 05:00:00
- End Date: 2022-05-04 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.25 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest